Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Temozolomide Monotherapy for Second-Line Treatment of Neuroendocrine Carcinomas After Platinum-Based Therapy
2016-005238-31Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in neuroendocrine carcinoma (NEC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Started Jun 2021; status: completed.
02
Drugs
temozolomide
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2016-005238-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005238-31.